Sat.May 29, 2021 - Fri.Jun 04, 2021

article thumbnail

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

pharmaphorum

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. The Danish drugmaker has acquired exclusive rights outside Japan to Heartseed’s HS-001 therapy based on heart muscle cells (cardiomyocytes) derived from human stem cells, and is due to start the phase 1/2 LAPiS trial in Japan later this year.

article thumbnail

Novartis reports 'clinically relevant' survival data for Lutathera

Pharma Times

The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours

121
121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New patent for Vifor Fresenius drug VELPHORO

Drug Patent Watch

Annual Drug Patent Expirations for VELPHORO Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Vifor Fresenius drug VELPHORO appeared first on DrugPatentWatch - Make Better Decisions.

98
article thumbnail

Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment

Outsourcing Pharma

The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drugâs effectiveness in preventing worsening of symptoms and hospitalization.

Hospitals 107
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

What HCPs think about blood clots linked to COVID-19 vaccines

pharmaphorum

In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. The formation of blood clots is a necessary process in order for the body to repair damage caused by injury and to slow down bleeding. However, when blood clots form inappropriately, this limits blood flow through vessels and can pose a significant health risk.

Vaccines 105
article thumbnail

Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’

Pharma Times

Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months

145
145

More Trending

article thumbnail

Skin-patch COVID-19 vaccine could offer enhanced antibody responses, according to preclinical data

Outsourcing Pharma

COVID-19 vaccination via Vaxxasâ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.

article thumbnail

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

pharmaphorum

AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when used as adjuvant therapy. Giving Lynparza (olaparib) to women with BRCA-positive, HER2-negative breast cancer straight after chemotherapy and surgery to remove the tumour reduced the risk of recurrence, secondary cancers or death by 42% compared to placebo after 2.5 years of follow-up.

article thumbnail

'Indian' variant of coronavirus now dominant strain in the UK

Pharma Times

Officials warned that early evidence suggests there may be an increased risk of hospitalisation for Delta compared to the Alpha (Kent) strain

123
123
article thumbnail

Which pharmaceutical companies have the most suspension dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most suspension dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most suspension dosed drugs…. The post Which pharmaceutical companies have the most suspension dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Ketamine as a Depression Treatment Saved Me

NY Times

I tried everything to treat my depression. Ketamine is the one thing that worked.

112
112
article thumbnail

Prostate Cancer Drug Development Summit

pharmaphorum

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. With sessions on both early and advanced stages of prostate cancer (Non-Metastatic Castrate-Resistant Prostate Cancer (nmCRPC) and Metastatic Castrate-Resistant Prostate Cancer (mCRPC) , this is a conversation not to mi

article thumbnail

Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma

Pharma Times

Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM

130
130
article thumbnail

Which pharmaceutical companies have the most SPCs in Estonia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Estonia. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Estonia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Despite COVID-19, pharma R&D funding at all-time high: IQVIA

Outsourcing Pharma

According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels.

85
article thumbnail

Time for a NICE change

pharmaphorum

The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the world has changed over its history, NICE is coming to the end of a period of review and consultation on their processes and methods. Leela Barham takes stock. This article appears in our digital magazine Deep Dive: Market Access 2021.

article thumbnail

FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder

Pharma Times

Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021

128
128
article thumbnail

New patent for Chiesi drug FERRIPROX

Drug Patent Watch

Annual Drug Patent Expirations for FERRIPROX Ferriprox is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are five patents protecting…. The post New patent for Chiesi drug FERRIPROX appeared first on DrugPatentWatch - Make Better Decisions.

87
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AstraZeneca taps Reify Health platform to boost breast cancer trials

Outsourcing Pharma

The pharma firm plans to use the StudyTeam platform to accelerate development, ease site burdens and improve patient matching for breast cancer studies.

73
article thumbnail

Study finds “alarming” hike in antidepressant costs during COVID-19

pharmaphorum

Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in England during 2020, adding £139 million to NHS costs. The team from the University of Huddersfield said the findings highlight an “urgent need” for new mental health strategies to make sure antidepressants are being used appropriately, particularly in adolescents and younger adults.

article thumbnail

Amgen and Kyowa Kirin agree to jointly develop eczema med

Pharma Times

KHK4083 is an anti-OX40, fully human monoclonal antibody in development for the treatment of atopic dermatitis

116
116
article thumbnail

Which pharmaceutical companies have the most SPCs in Spain?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Moderna Seeks Full F.D.A. Approval for Covid Vaccine

NY Times

The company’s application follows the move by Pfizer and BioNTech to seek full approval last month. The vaccines already have emergency use authorization in the United States.

article thumbnail

FDA grants swift approval to Cognoa’s digital device for autism diagnosis

pharmaphorum

The FDA has approved a digital device developed by Cognoa that can be used to diagnose autism spectrum disorder (ASD), just a few weeks after it was filed for approval. Cognoa says the artificial intelligence (AI) based device is the first to be authorised by the US regulator that can help doctors diagnose autism in primary care, and will be launched “in the coming months” At the moment, autism can be difficult to diagnose as there are no medical markers to confirm its presence.

article thumbnail

WHO authorises Sinovac’s COVID-19 vaccine for emergency use

Pharma Times

A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing

Vaccines 108
article thumbnail

New patent expiration for Cumberland Pharms drug VIBATIV

Drug Patent Watch

Annual Drug Patent Expirations for VIBATIV Vibativ is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent expiration for Cumberland Pharms drug VIBATIV appeared first on DrugPatentWatch - Make Better Decisions.

75
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Italy sees hike in biotech R&D investments, at rate higher than EU average

Outsourcing Pharma

A robust research and innovation ecosystem makes Italy an attractive life sciences hotspot, according to a post from an Italian trade delegation at Bio Digital 2021.

69
article thumbnail

UK is talking to AstraZeneca about beta variant COVID jab

pharmaphorum

The UK government is talking to AstraZeneca about ordering additional doses of its COVID-19 vaccine that will target the beta variant of SARS-CoV-2 virus first identified in South Africa, according to Health Secretary Matt Hancock. The AZ/Oxford University vaccine and other shots from Pfizer/BioNTech and Moderna are known to have less efficacy against the beta variant – also known as B.1.351 – which is estimated to be around 50% more transmissible than earlier strains.

article thumbnail

J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients

Pharma Times

IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement

118
118
article thumbnail

New patent for Evoke Pharma drug GIMOTI

Drug Patent Watch

Annual Drug Patent Expirations for GIMOTI Gimoti is a drug marketed by Evoke Pharma Inc and is included in one NDA. There are two patents protecting this drug. This drug…. The post New patent for Evoke Pharma drug GIMOTI appeared first on DrugPatentWatch - Make Better Decisions.

75
article thumbnail

‘HIV remains a pandemic of inequalities’: The fight against HIV/AIDS, 40 years on

Outsourcing Pharma

June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital â featuring Dr. Anthony Fauci, Director of NIAID at the US NIH â will focus on four decades of innovation as well as the critical importance of collaboration and investment moving forward.

65